Medical technology company SciBase Holding AB (SciBase) (STO:SCIB) reported on Wednesday that a new clinical study has been published, titled "Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy."

The study was published in the journal Melanoma Research and shows the Nevisense significantly improves US clinician's decision-making beyond dermoscopy.

SciBase said this study included 231 US Dermatologists making a total of 33.957 biopsy decisions. Participants showed a statistically significant improvement in correct biopsy decisions beyond their dermoscopic evaluation when integrating the Nevisense result. With Nevisense, Dermatologists identified more melanomas for biopsy; their sensitivity increasing from 85.2% to 91.1%.

Simon Grant, CEO of SciBase, remarked: "This is a very important study and result for SciBase as it quantifies the improvement in clinical decision-making possible with Nevisense compared to visual methods that are today considered the standard of care. As expected, the study showed that dermoscopy improved decision making over naked eye assessment, but more importantly it showed that using Nevisense further improved clinician performance by at least as much again. Adding Nevisense clearly resulted in the best clinical management decisions. This is one of several publications that shows that Nevisense has a significant role in the challenging process for clinicians to identify malignancies."

Headquartered in Stockholm, Sweden, SciBase has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase combines artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. The company's products include Nevisense and Nevisense Go. The company added that Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe.